Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer

In the TroFuse-005 trial, Sac-TMT reduced the risk of death by 32% and the risk of disease progression or death by 41% compared with chemotherapy. The headline reports a positive clinical-trial result but provides no further details on the trial or market reaction.